ProMIS Neurosciences Inc PMN

@ the Bell: TSX powers through to close week higher

[M101]

Looks like a stop-loss on Wednesday morning momentarily took the price down to 1.40, so where was the market? And you think it takes a rumour to hold the price down? 

[Lynx9]

Isn't it time for another juicy rumour to start circulating amongst the faithful to hold the price at $2us.

[Jonathon Brown]

Canada’s main stock index inched up on Friday. The only drag on the TSX was a drop in the energy sector while mining led gains. read article.

[M101]

Probably not fair to blame the "scientific community" for being slow to get off the plaque train, the science hopped off 1-3 decades ago so the "forward" motion we see now is just

[Gbathat]

Timing is everything.  Experienced investors are looking at the same milestones as us and saying, why get in now when my money could be growing elsewhere?  But we are getting close to

[BottomBroker]

You're unusually optimistic....

[goldtech]

Why is it we don't get any credit for PMN310? Simple, it has been decades saying that plaque causes Alzheimer's. Now the scientific community is just starting to recognize that toxic oligomers

[Jonathon Brown]

While energy gains propel the TSX, industrials get attention from the EV market and investors navigate another week of mining sector activity. read article.

[PressRelease]

Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody...read article.

[goldtech]

The incidence of Alzheimer's disease (AD) is growing every day and finding an effective treatment is becoming more vital. Amyloid-β (Aβ) has been the focus of research for several decades. The

[goldtech]

Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease.  I don't know how you can

[farmerlucy]

A deal with a Pharma company that could leverage Promis's platform, Alzhemers might not work out, perhaps ALS , PD, vaccines have a better shot.  Diagnostics clearly heading into alzheimers

[M101]

Yup, 1A unlikely to be a market mover.  I cannot imagine the investor out there sitting on 1a results.   Granted Pfizer made a killing (literal and figurative) with a "vaccine"

[farmerlucy]

I wish you were right but the fact is Promis over the last couple of years has just been testing animals and humans not alzheimers patients. Numerous companies have passed phase 1 safety results

[goldtech]

When the 1A results are released in June the market will begin to put us on their radar screen and news letter writers will comment to their clients. Our ridiculous market cap will be gone and

[M101]

I wasn't aware I had a conspiracy theory, how does it go? 

[goldtech]

Partnership, joint venture, collaboration, call it what you want but if we succeed then credits will be afforded to the entire platform. This all stems on the two scenarios and if successful, big